Evidence map›Paper›PMID 19116921›Full record

ArticleArthritis and rheumatism2009

Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region.

Bo Ding, Leonid Padyukov, Emeli Lundström, Mark Seielstad, Robert M Plenge, Jorge R Oksenberg, Peter K Gregersen, Lars Alfredsson, Lars Klareskog

Erratum issued Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Arthritis and rheumatism, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04092244 (CTHRC1 as a New Biomarker in Diagnosis of Rheumatoid Arthritis and Its Role in Seronegative Patients.), which is not on this map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04092244 unknown statusnot on this mapstarted 2020, after this paper: background citation

CTHRC1 as a New Biomarker in Diagnosis of Rheumatoid Arthritis and Its Role in Seronegative Patients.

TypeobservationalSponsorAssiut UniversityRan2020 to 2021Enrolled90ConditionsRheumatoid ArthritisArmsCTHRC1 biomarker
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Epidemiology and Risk Factors for Rheumatoid Arthritis Development.Mediterranean journal of rheumatology · 2023
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Frontiers in immunology · 2021
    Article
  15. Observational
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Bo DingKarolinska Institutet, Stockholm, Sweden. Bo.Ding@ki.se
Leonid Padyukov
Emeli Lundström
Mark Seielstad
Robert M Plenge
Jorge R Oksenberg
Peter K Gregersen
Lars Alfredsson
Lars Klareskog
Karolinska University Hospital · SEKarolinska Institutet · SEFeinstein Institute for Medical Research · USGenome Institute of Singapore · SGHarvard University · USUniversity of California, San Francisco · US

Funding

Systemic Lupus Erythematosus and Ulcerative Colitis StudyU19AI067152 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAUSER, STEPHEN L · 2005 to 2009
$10.1M
NARAC The Genetics of Rheumatoid ArthritisR01AR044422 · NIAMS · NORTH SHORE UNIVERSITY HOSPITAL · PI GREGERSEN, PETER K. · 1997 to 2011
$6.0M
Mapping HIV/AIDS genes with haplotype-based strategiesK08AI055314 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI PLENGE, ROBERT M · 2004 to 2008
$585k
NIAID NIH HHS K08 AI055314NIAID NIH HHS K08-AI-55314-3NIAID NIH HHS U19 AI067152NIAID NIH HHS U19-AI-067152NIAMS NIH HHS R01 AR044422NIAMS NIH HHS R01-AR-44422
6 · The paper itself

Abstract

objectiveTo identify additional variants in the major histocompatibility complex (MHC) region that independently contribute to risk in 2 disease subsets of rheumatoid arthritis (RA) defined according to the presence or absence of antibodies to citrullinated protein antigens (ACPAs).

methodsIn a multistep analytical strategy using unmatched as well as matched analyses to adjust for HLA-DRB1 genotype, we analyzed 2,221 single-nucleotide polymorphisms (SNPs) spanning 10.7 Mb, from 6p22.2 to 6p21.31, across the MHC. For ACPA-positive RA, we analyzed samples from the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) and the North American Rheumatoid Arthritis Consortium (NARAC) studies (totaling 1,255 cases and 1,719 controls). For ACPA-negative RA, we used samples from the EIRA study (640 cases and 670 controls). Plink and SAS statistical packages were used to conduct all statistical analyses.

resultsA total of 299 SNPs reached locus-wide significance (P<2.3x10(-5)) for ACPA-positive RA, whereas surprisingly, no SNPs reached this significance for ACPA-negative RA. For ACPA-positive RA, we adjusted for known DRB1 risk alleles and identified additional independent associations with SNPs near HLA-DPB1 (rs3117213; odds ratio 1.42 [95% confidence interval 1.17-1.73], Pcombined=0.0003 for the strongest association).

conclusionThere are distinct genetic patterns of MHC associations in the 2 disease subsets of RA defined according to ACPA status. HLA-DPB1 is an independent risk locus for ACPA-positive RA. We did not identify any associations with SNPs within the MHC for ACPA-negative RA.

Indexed as

Antibody SpecificityArthritis, RheumatoidAutoantibodiesCitrullineGenetic Predisposition to DiseaseGenotypeHLA-DR AntigensHLA-DRB1 ChainsHumansLinkage DisequilibriumPeptides, CyclicPolymorphism, Single NucleotideRisk FactorsAutoantibodiesCitrullinecyclic citrullinated peptideHLA-DR AntigensHLA-DRB1 ChainsPeptides, Cyclic

Identifiers

PMID19116921
PMCPMC2874319
OpenAlexW2017548224

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.